CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services
adnkronos.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adnkronos.com Daily Mail and Mail on Sunday newspapers.
CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
11 maggio 2021 14:35
Fonte: Adnkronos
#chimica-e-farmacia
- MONTREAL, May 11, 2021 /PRNewswire/ CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ( Reveal ), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta s position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.
Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally. Reveal s imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data.